Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos


Treatment of evolocumab for 26 weeks showed an increase in the minimum fibrous cap thickness by OCT, reduction in maxLCBI 4 mm by NIRS and reduction in atheroma volume by IVUS in non-obstructive lesions of patients with stable CAD in the YELLOW III study.